Despite political and economic challenges, Merck CEO Robert Davis remains optimistic about the company’s ophthalmology business. The recent acquisition of EyeBio brought a $1.3 billion boost, focusing on the trispecific antibody Restoret for diabetic macular edema (DME) and neovascular age-related macular degeneration (AMD). The Phase IIb/III trial for Restoret in DME, known as BRUNELLO, commenced in September 2024 and is expected to conclude by the end of 2027. With this strategic move, Merck aims to capitalize on blockbuster opportunities in the pharma landscape.
This increased focus on R&D investment signifies a commitment to innovation and growth in the pharmaceutical industry. The development of Restoret showcases the company’s dedication to addressing critical medical needs, such as DME and AMD. As Merck navigates through the challenges posed by the current political and economic environment, their proactive approach to portfolio management sets a precedent for other pharma companies. By prioritizing research and development despite external pressures, Merck demonstrates a long-term vision that aims to drive success and bring novel treatments to patients in need.
Read more from biospace.com
